Offstream
news

---

Changes

1. Pfizer formally ends its vaccine trial with a 95% success rate.
   2020-11-18 19:04:23 (First version)
2. Pfizer formally ends its vaccine trial with a 95% success rate and will be submit the regulatory approval "within days".
   2020-11-19 01:04:13 (Update)
3. Pfizer formally ends its vaccine trial with a 95% success rate and will submit a regulatory approval "within days".
   (Current version)

---

Related

Health Canada approves the use of Pfizer's anti-COVID-19 viral drug Paxlovid for people over the age of 18 years who are at risk of severe disease and death.
2022-01-17

Bahrain authorizes the emergency use of Pfizer's anti-viral oral drug Paxlovid for adults over the age of 18 years.
2022-01-1

Pfizer and the Medicines Patent Pool sign a global licensing agreement that will allow Pfizer's experimental COVID-19 oral drug Paxlovid to be manufactured under a royalty-free license in 95 low and middle-income countries.
2021-11-16

In a study published by the National Health Service, the Pfizer vaccine has been found to reduce hospitalizations in elderly people by 75%.
2021-04-14

Vaccine developer Pfizer announces that lab studies have concluded that the joint Pfizer–BioNTech vaccine remains effective against mutation variants of the SARS-CoV-2 virus, including Variant of Concern 202012-01 and the 501.V2 variant.
2021-01-8

The World Health Organization lists the Pfizer-BioNTech vaccine for emergency use.
2020-12-31

Spain receives its first shipment of the Pfizer-BioNTech vaccine tozinameran in Guadalajara, a day before the country begins its vaccination programme.
2020-12-26

Prime Minister Lee Hsien Loong says that Singapore has approved the Pfizer-BioNTech vaccine. The country expects to receive shipments of the vaccine by the end of the year and to vaccinate 5.7 million people for free by the third quarter of 2021.
2020-12-14

Pfizer and BioNTech apply for an emergency use authorization from the U.S. Food and Drug Administration for their vaccine. If the application is approved, the vaccine will likely be limited and rolled out in phases.
2020-11-20

The European Medicines Agency announces that they will launch a review for vaccines developed by Pfizer and BioNTech.
2020-10-6